
# BioCLIA<sup>®</sup> Autoimmune Control Set

# **CENP-B**

# **CENPB Assay Controls**



# BioCLIA® Autoimmune Control Set,

### CENP-B

#### **Intended Use**

The BioCLIA Autoimmune Control Set, CENP-B is intended for the quality control purposes of the BioCLIA CENP-B performed on the BioCLIA® 1200 and BioCLIA® 6500.

#### **Catalog Numbers**

MY00313 (2 X 1 mL) MY00364 (4 X 1 mL)

#### **Summary and Principles of the Procedure**

Anti-nuclear antibodies (ANAs) are a class of auto-antibodies with different binding affinities specific to different nucleus antigens. Generally, ANAs include extractable nuclear antigen (ENA) antibodies and un-extractable nuclear antigen antibodies. Determination of ANAs has significant correlation to the diagnosis of Sharp Syndrome, Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, progressive systemic sclerosis, polymyositis/dermatomyositis, overlap syndrome, and limited types of progressive systemic sclerosis (CREST syndrome).

Anti-centromere antibodies are associated with limited cutaneous systemic sclerosis, also known as CREST syndrome, primary biliary cirrhosis and proximal scleroderma. There are six known antigens, which are all associated with the centromere; CENP-A to CENP-F in which CENP-B is the main antigen. It is an 80 kDa DNA binding protein, located in the center of the chromosome centromeric region. It is related to the formation and function of centromere and kinetochore. <sup>2</sup>

Anti-CENP antibodies are of great significance to the diagnosis of primary biliary cirrhosis (PBC), or limited systemic sclerosis especially the CREST subtypes (patients with calcification, Renault's phenomenon, esophageal movement disorders, hard finger (toe) syndrome or blood capillary expansion). In addition, anti-CENP antibodies can be detected in patients with the Renault syndrome, tumor and other rheumatic diseases such as SLE, sjogren syndromes or rheumatoid arthritis. <sup>3</sup>

## Materials supplied

• CENP-B Control 1 A tube contains 1mL, ready to use reagent. Control 1 contains human antibodies to CENP-B in stabilizers and preservatives.

Preservatives: 0.0015% < Proclin 300 < 0.6%.

• CENP-B Control 2 A tube contains 1mL, ready to use reagent. Control 2 contains human antibodies to CFNP-B in stabilizers and preservatives.

Preservatives: 0.0015% < Proclin 300 < 0.6%.

Target value and acceptable range for the controls are indicated on control information sheet in each kit

#### **Warnings and Precautions**

The human derived material in this product was tested by FDA approved methods and found nonreactive for Hepatitis B Surface Antigen (HBsAg), Anti-HCV and HIV 1/2 antibodies. Handle as if potentially infectious. <sup>4</sup> Avoid contacting with skin and eyes. Do not empty into drains. Wear suitable protective clothing.

#### Precautions:



Human serum is added in the controls.



Proclin 300 is added in the controls at

concentration between 0.0015% - 0.6%.

- The product is for in vitro diagnostic use only.
- Do not use any controls beyond their expiration dates. Do not mix controls from different lots unless specified.
- Instructions must be carefully followed for using and storing of controls. Any modification in procedure may interfere with the results. Controls and contaminated vials must be handled strictly following safety guidelines or rules of biological hazards to ensure the users' and environmental safety.
- Controls contain chemical and biological components. Avoid ingesting or splashing onto skin and mucous membrane. If direct contact with controls happens, rinse the contact surface with plenty of water immediately and see a doctor if necessary.

#### **Storage Conditions**

The kit is stable until the expiration date, if it is stored and handled as directed. Routine store the kit in refrigerator(2-8°C). Once a control tube is opened, it is good for a total of 15 times, no more than 2 hours per time when kept uncapped, onboard the instrument, after which the reagent must be discarded. Three freeze-thaw cycles before testing has no effect on the kit reagents.

## **Assay Procedure**

Note that, for obtaining optimal performance, it is important to perform all routine maintenance procedures as defined in the BioCLIA® 1200 and BioCLIA® 6500 User Manual.

See the BioCLIA® 1200 and BioCLIA® 6500 User Manual for preparation, setup, dilutions, adjustment, assay and quality control procedures.

The control procedure can be done before running the specimens each day. Users also can adjust the

control procedure period according to their own lab frequency.

Revision 9

#### Limitations

This product is designed as controls for monitoring the performance of the BioCLIA CENP-B. These controls are subjected to the limitations of the assay system. Deviations may indicate possible problems with one or more components in the test system.

#### References

- 1. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Advances in Immunology 1982;33:167-240.
- 2. Imboden JB, Hellmann DB, Stone JH. Current rheumatology diagnosis & D, treatment. A Lange Medical Book 2007.
- 3. Nakamura M, Kondo H, Mori T, Komori A, Matsuyama M, Ito M, et al. Anti gp210 and anti centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45:118-27.
- 4. Richmond JY, Mckinney RW. Biosafety in microbiological and biomedical laboratories: U.S.GPO. 1999.







HOB Biotech Group Co., Ltd

C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park,

Suzhou, Jiangsu, 215123, China

REGISTRANT/MANUFACTURE: HOB Biotech Group

Co., Ltd

#### ADDRESS/LOCATION:

C6 Building, No. 218 Xinghu Road, Suzhou Industrial Park, Suzhou, Jiangsu, 215123 China

**CONTACT INFORMATION:** TEL (+86)512-69561996

Fax (+86)512-62956652

WEBSITE: www.hob-biotech.com

**CUSTOMER SERVICE:** HOB Biotech Group Co., Ltd **CUSTOMER SERVICE CONTACT:** TEL (+86)4008601202



**EUROPE REPRESENTATIVE:** Emergo Europe

ADDRESS/LOCATION:

Prinsessegracht 20, 2514 AP The Hague, The

Netherlands

#### **Technical Assistance**

For technical assistance, contact your National Distributor.

17<sup>th</sup> April 2019